[{"orgOrder":0,"company":"Codexis","sponsor":"Nestle Health Sciences SA","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Codexis and Nestl\u00e9 Health Science Sign Development Agreement to Advance Therapeutic Candidate towards Clinical Studies and Extend Strategic Collaboration Agreement","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Discovery","country":"U.S.A","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"January 2020","url1":"","url2":"","graph1":"Undisclosed","graph2":"Codexis"},{"orgOrder":0,"company":"Second Genome","sponsor":"Gilead Sciences","pharmaFlowCategory":"D","amount":"$1,538.0 million","upfrontCash":"$38.0 million","newsHeadline":"Gilead Sciences and Second Genome Announce Strategic Collaboration in Biomarker and Inflammatory Bowel Disease Drug Discovery","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Discovery","country":"U.S.A","productType":"Undisclosed","productStatus":"Undisclosed","date":"April 2020","url1":"","url2":"","graph1":"Undisclosed","graph2":"Second Genome"},{"orgOrder":0,"company":"Celsius Therapeutics","sponsor":"University of Oxford","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Celsius Therapeutics Signs Research Agreements with Leading Academic Centers to Develop Insights into Inflammatory Bowel Disease Biology","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Discovery","country":"U.S.A","productType":"Undisclosed","productStatus":"Undisclosed","date":"July 2020","url1":"","url2":"","graph1":"Undisclosed","graph2":"Celsius Therapeutics"},{"orgOrder":0,"company":"Scipher Medicine","sponsor":"Galapagos","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Scipher Medicine and Galapagos Sign Collaboration in Inflammatory Bowel Disease","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Discovery","country":"U.S.A","productType":"Undisclosed","productStatus":"Undisclosed","date":"August 2020","url1":"","url2":"","graph1":"Undisclosed","graph2":"Scipher Medicine"},{"orgOrder":0,"company":"Novome Biotechnologies","sponsor":"Genentech","pharmaFlowCategory":"D","amount":"$605.0 million","upfrontCash":"$15.0 million","newsHeadline":"Novome Biotechnologies and Genentech Enter into a Strategic Collaboration to Develop Targets Against Inflammatory Bowel Disease","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Discovery","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2021","url1":"","url2":"","graph1":"Large molecule","graph2":"Novome Biotechnologies"},{"orgOrder":0,"company":"Kallyope","sponsor":"Sosei Group Corporation","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Sosei Heptares and Kallyope Enter Collaboration to Identify and Validate Novel Gastrointestinal GPCR Targets for Drug Discovery","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Discovery","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Kallyope"},{"orgOrder":0,"company":"Celsius Therapeutics","sponsor":"Applied BioMath","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Applied BioMath, LLC Announces a Continuation of their Collaboration with Celsius Therapeutics for Systems Pharmacology Modeling in Inflammatory Bowel Disease","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Discovery","country":"U.S.A","productType":"Undisclosed","productStatus":"Undisclosed","date":"October 2022","url1":"","url2":"","graph1":"Undisclosed","graph2":"Celsius Therapeutics"},{"orgOrder":0,"company":"Sosei Heptares","sponsor":"University of Oxford","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Sosei Heptares Enters R&D Agreements with the University of Oxford and KU Leuven to Identify and Validate Key GPCRs Driving Gastrointestinal and Immune Disorders","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Discovery","country":"JAPAN","productType":"Undisclosed","productStatus":"Undisclosed","date":"December 2022","url1":"","url2":"","graph1":"Undisclosed","graph2":"Sosei Heptares"},{"orgOrder":0,"company":"Cytoreason","sponsor":"Sanofi","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"CytoReason to License Its IBD Disease Model to Sanofi in Expanded Multiyear, Multimillion Dollar Deal","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Discovery","country":"ISRAEL","productType":"Undisclosed","productStatus":"Undisclosed","date":"January 2023","url1":"","url2":"","graph1":"Undisclosed","graph2":"Cytoreason"},{"orgOrder":0,"company":"Sonoma Biotherapeutics","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"D","amount":"$120.0 million","upfrontCash":"$75.0 million","newsHeadline":"Regeneron and Sonoma Biotherapeutics Announce Collaboration to Discover, Develop and Commercialize Treg Cell Therapies for Autoimmune Diseases","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Discovery","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2023","url1":"","url2":"","graph1":"Cell and Gene therapy","graph2":"Sonoma Biotherapeutics"},{"orgOrder":0,"company":"TScan Therapeutics","sponsor":"Amgen Inc","pharmaFlowCategory":"D","amount":"$530.0 million","upfrontCash":"$30.0 million","newsHeadline":"Amgen and TScan Therapeutics Announce Collaboration to Identify Novel Targets in Crohn's Disease","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Discovery","country":"U.S.A","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"May 2023","url1":"","url2":"","graph1":"Undisclosed","graph2":"TScan Therapeutics"}]
Find Clinical Drug Development Pipelines & Deals | PipelineProspector
Under the terms of agreement, Amgen will evaluate a variety of modalities to create therapeutics based on targets discovered by TScan's proprietary target discovery platform, TargetScan, to identify the antigens recognized by T cells in patients with Crohn's disease.
Regeneron and Sonoma will research and develop Treg-based Cell Therapies for ulcerative colitis, Crohn’s disease and two other undisclosed indications, through VelociSuite® technologies for the discovery and characterization of fully human antibodies and T cell receptors.
The collaboration will support Sanofi’s use of CytoReason’s computational disease models to develop new targets for inflammatory bowel disease (IBD), to identify patient subtypes and pair them with IBD targets.
The focus of the agreements is to apply the innovative technologies and research capabilities of the respective academic groups to identify, validate and prioritize key GPCRs driving gastrointestinal and immune disorders, including IBD, as targets for SBDD.
Under the agreement, Celsius Therapeutics will collaborate for the development of a systems pharmacology model of a monoclonal antibody for the treatment of inflammatory bowel disease (IBD).
The agreement will leverage Sosei Heptares’ GPCR Diversified Compound Library and GPCR expertise with the innovative Kallyope gut-brain axis platform, which combines single-cell sequencing, circuit mapping, computational biology and enteroid phenotypic screening.
Under the terms of the agreement, Novome will have responsibility for research activities up to initiation of IND-enabling preclinical studies for this multi-target collaboration.
Lead Product(s):
Genetically Engineered Microbial Medicines
Scipher and Galapagos will jointly validate a suite of novel IBD targets discovered by Scipher after which Galapagos has the exclusive option to progress up to five targets into further drug discovery and development.
Celsius will partner with leading academic scientists to access patient tissue samples and apply its proprietary single-cell genomics platform and machine learning capabilities to discover new insights into inflammatory bowel disease (IBD).
Second Genome will utilize its proprietary Microbiome Analytics Platform™ to identify novel biomarkers associated with clinical response to Gilead’s investigational medicines.